Physician profile
Mini A Panikar
NPI 1255399432
$7,774.82
in general payments reported to CMS, 2019-2025
36 companies · $1,856 in 2025
The $1,856 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,191 · 2020: $295 · 2021: $214 · 2022: $882 · 2023: $1,469 · 2024: $1,868 · 2025: $1,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,113 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,112.92 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $877.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $841.57 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $819.60 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $574.99 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $558.50 | 2019-2025 | |
| Lilly USA, LLC | $456.59 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Exact Sciences Corporation | $402.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $402.08 | 2019-2025 | Capvaxive, Gardasil 9, Pneumovax 23 |
| Pfizer INC. | $381.96 | 2019-2025 | |
| Astellas Pharma US INC | $370.89 | 2019-2025 | Veozah |
| Amgen INC. | $295.39 | 2019-2025 | Prolia, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.51 | 2019-2025 | Synjardy, Jardiance, Glyxambi |
| Amarin Pharma, INC. | $218.97 | 2019-2022 | |
| Horizon Therapeutics Plc | $159.07 | 2023 | Krystexxa |
| Hologic Sales and Service, LLC | $148.04 | 2025 | Aptima |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mini Panikar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.